Reciprocally, in publicly available data, SS18-SSX knockdown in HS-SY-II (SS18-SSX1) and SYO-I (SS18-SSX2) synovial sarcoma lines led to a concomitant decrease in BCOR (ref. 16) (Extended Data Fig. 4b). Here, SS18 is linked to synovial sarcoma.